Behavioral symptoms related to cognitive impairment

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 1443-1455

  Dillon, Carol ^a   Serrano, Cecilia M ^a   Castro, Diego ^a   Leguizamón, Patricio Perez ^a   Heisecke, Silvina L ^a,b   Taragano, Fernando E ^a  

^a CEMIC   (Argentina)

^b CONICET ^*  (Argentina)

Author keywords

Behavioral or neuropsychiatric symptoms; Cognitive impairment; Dementia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; ESTROGEN; HIRUDIN; HYPNOTIC AGENT; MELATONIN; MOOD STABILIZER; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TRAZODONE; VALPROIC ACID;

ALZHEIMER DISEASE; BEHAVIOR DISORDER; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA; CAREGIVER BURDEN; CEREBROVASCULAR DISEASE; COGNITION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG FATALITY; FRONTOTEMPORAL DEMENTIA; HOSPITALIZATION; HUMAN; INSTITUTIONALIZATION; MENTAL DISEASE; MILD BEHAVIORAL IMPAIRMENT; MILD COGNITIVE IMPAIRMENT; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC SYMPTOM; NONHUMAN; REVIEW; RISK; UNSPECIFIED SIDE EFFECT;

EID: 84884406952     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S47133     Document Type: Review

References (102)

1. Steinberg M, Shao H, Zandi P, et al; Cache County Investigators. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170-177.
2. Lyketsos CG, Breitner JC, Rabins PV. An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease. Int J Geriatr Psychiatry. 2001;16(11):1037-1042.
3. Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry. 2008;65(10): 1193-1198.
4. Demey I, Zimerman M, Allegri RF, Serrano CM, Taragano FE. Neuropsychiatric symptoms in mild cognitive impairment. Vertex. 2007;18(74):252-257. Spanish.
5. Palmer K, Di Iulio F, Varsi AE, et al. Neuropsychiatric predictors of progression from amnestic-mild cognitive impairment to Alzheimer's disease: the role of depression and apathy. J Alzheimers Dis. 2010;20(1): 175-183.
6. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol. 2004;61(8): 1290-1293.
7. Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70(4):584-592.
8. Allegri RF, Sarasola D, Serrano CM, et al. Neuropsychiatric symptoms as a predictor of caregiver burden in Alzheimer's disease. Neuropsychiatr Dis Treat. 2006;2(1):105-110.
9. Rojas G, Bartoloni L, Dillon, C, Serrano CM, Iturry M, Allegri RF. Clinical and economic characteristics associated with direct costs of Alzheimer's, frontotemporal and vascular dementia in Argentina. Int Psychogeriatr. 2011;23(4):554-561.
10. Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8 Suppl 3:497-500.
11. Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision. Arlington (VA): American Psychiatric Press Inc, 2000.
13. World Health Organization. International Codification of Diseases, 10th edition (ICD 10). 1990.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-5. Arlington (VA): American Psychiatric Press Inc, 2013.
15. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987;48 Suppl:9-15.
16. Levin HS, High WM, Goethe K, et al. The neurobehavioral rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry. 1987;50(2):183-193.
17. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356-1364.
18. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12): 2308-2314.
19. de Medeiros K, Robert P, Gauthier S, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22(6):984-994.
20. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement. 2011;7(5):532-539.
21. Hamilton M. A rating scale for depression. Neurol Neurosurg Psychiatry. 1960;23:56-62.
22. Alexopoulos GS, Abrams RC, Young RC, Shamoian CS. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271-284.
23. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982-1983;17(1):37-49.
24. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):77-84.
25. Taragano FE, Allegri RF. Mild behavioral impairment: the early diagnosis. Int Psychogeriatr. 2003;15 Suppl 2:12. Abstract S002-002.
26. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):985-1992.
27. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
28. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475-1483.
29. Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord. 2004;18(1):17-21.
30. Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25(2):115-126.
31. Feldman H, Scheltens P, Scarpini E, et al. Behavioral symptoms in mild cognitive impairment. Neurology. 2004;62(7):1199-1201.
32. Copeland MP, Daly E, Hines V, et al. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord. 2003;17(1):1-8.
33. Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology. 2007;68(19):1596-1602.
34. Butters MA, Young JB, Lopez O, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10(3):345-357.
35. Robert PH, Berr C, Volteau M, et al; PréAL study. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. Clin Neurol Neurosurg. 2006;108(8):733-736.
36. Apostolova LG, Cummings JL. Psychiatric manifestation in dementia. Continuum Lifelong Learning Neurology. 2007;13(2):165-179.
37. Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26(4):364-372.
38. Hallikainen I, Koivisto AM, Paajanen T, et al. Cognitive and neuropsychiatric symptom differences in early stages of Alzheimer's disease: Kuopio ALSOVE study. Dementia Geriatr Cogn Dis Extra. 2012;2: 209-218.
39. Machnicki G, Allegri RF, Dillon C, Serrano CM, Taragano FE. Cognitive, functional and behavioral factors associated with the burden of caring for geriatric patients with cognitive impairment or depression: evidence from a South American sample. Int J Geratr Psychiatry. 2009;24(4):382-389.
40. Braak H, Del Tredici K, Braak E. Spectrum of pathology. In: Petersen RC, editor. Mild Cognitive Impairment: Aging to Alzheimer's Disease. New York: Oxford University Press, Inc; 2003:149-189.
41. Jicha GA, Carr SA. Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease. J Alzheimer Dis. 2010;19(1):253-272.
42. Lam LC, Leung T, Lui VW, Leung VP, Chiu HF. Association between cognitive function, behavioral syndromes and two-year clinical outcome in Chinese subjects with late-onset Alzheimer's disease. Int Psychogeriatr. 2006;18(3):517-526.
43. Peters KR, Rockwood K, Black SE, et al. Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology. 2006;66(4):523-528.
44. Tekin S, Fairbanks LA, O'Connor S, Rosenberg S, Cummings JL. Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences. Am J Geriatr Psychiatry. 2001;9(1):81-86.
45. Starr JM, Lonie J. Relationship between behavioural and psychological symptoms of dementia and cognition in Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(5):343-347.
46. Tractenberg RE, Weiner MF, Cummings JL, Patterson MB, Thal LJ. Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach. J Neuropsychiatry Clin Neurosci. 2005;17(1):51-60.
47. Harwood DG, Barker WW, Ownby RL, Duara R. Relationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's disease. Int J Geriatr Psychiatry. 2000;15(5):393-400.
48. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46(1): 130-135.
49. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98-104.
50. Mitchell RA, Herrmann N, Lanctôt KL. The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci Ther. 2011;17(5):411-427.
51. Tunnard C, Whitehead D, Hurt C, et al; AddNeuroMed Consortium. Apathy and cortical atrophy in Alzheimer's disease. Int J Geriatr Psychiatry. 2011;26(87):741-748.
52. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL. Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol. 2007;64(7):1015-1020.
53. Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD. Neuroimaging correlates of apathy and depression in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2009;21(3):259-265.
54. Lyketsos CG, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry. 2002;52:243-252.
55. Dillon C, Machnicki G, Serrano CM, Rojas G, Vazquez G, Allegri RF. Clinical manifestations of geriatric depression in a memory clinic: toward a proposed subtyping of geriatric depression. J Affect Disord. 2011;134(1-3):177-187.
56. Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord. 2004;17(1-2):55-64.
57. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8(1):29-34.
58. Emanuel JE, Lopez OL, Houck PR, et al. Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry. 2011;19(2):160-168.
59. Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991;48:619-624.
60. Mukaetova-Ladinska EB, Harrington CR, Xuereb J, Roth M, Wischik CM. Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease. In: Bergener M, Finkel SI, editors. Treating Alzheimer's and Other Dementias: Clinical Application of Recent Research Advances. New York: Springer; 1995:57-80.
61. Förstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry. 1994;165:53-59.
62. Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry. 2000;57:1165-1173.
63. Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011;122:117-135.
64. Pinto T, Lanctôt KL, Herrmann N. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. Ageing Res Rev. 2011;10:404-412.
65. Ismail Z, Nguyen MQ, Fischer CE, Schweizer TA, Mulsant BH, Mamo D. Neurobiology of delusions in Alzheimer's disease. Curr Psychiatry Rep. 2011;13:211-218.
66. Youn JC, Lee DY, Jhoo JH, Kim KW, Choo IH, Woo JI. Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD). Arch Gerontol Geriatr. 2011;52(3):258-263.
67. Orfei MD, Varsi AE, Blundo C, et al. Anosognosia in mild cognitive impairment and mild Alzheimer's disease: frequency and neuropsychological correlates. Am J Geriatr Psychiatry. 2010;18(12):1133-1140.
68. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546-1554.
69. Knopman DS, Petersen RC, Edland SD, Cha RH, Rocca WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62(3):506-508.
70. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology. 2002;58(2):198-208.
71. Viskontas I, Miller B. Frontotemporal dementia. Continuum Lifelong Learning Neurol. 2007;13(2):87-108.
72. Rabinovici GD, Miller BL. Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs. 2010;24(5):375-398.
73. Dillon C, Allegri RF. Disinhibition in psychogeriatry: differential diagnosis with frontotemporal dementia. Vertex. 2010;21(91):301-313. Spanish.
74. Mendez MF, Shapira JS, Woods RJ, Licht EA, Saul RE. Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord. 2008;25:206-211.
75. Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115(Pt 6):1783-1806.
76. Omar R, Sampson EL, Loy CT, et al. Delusions in frontotemporal lobar degeneration. J Neurol. 2009;256:600-607.
77. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology. 2002;58(2):198-208.
78. Liu W, Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology. 2004;62(5):742-748.
79. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11): 1006-1014.
80. Medina J, Weintraub S. Depression in primary progressive aphasia. J Geriatr Psychiatry Neurol. 2007;20:153-160.
81. Rosen HJ, Allison SC, Ogar JM, et al. Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology. 2006;67: 1752-1756.
82. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596-608.
83. Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry. 2008;20(4):396-404.
84. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia. CNS Drugs. 2010;24(9):729-739.
85. Herrmann N, Lanctôt KL. Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry. 2007;52(10): 630-646.
86. Karakaya T, Fußer F, Prvulovic D, Hampel H. Treatment options for tauopathies. Curr Treat Options Neurol. 2012;14(2):126-136.
87. Somme JH, Fernández-Martínez M, Molano A, Zarranz JJ. Neuropsychiatric Symptoms in Amnestic Mild Cognitive Impairment: Increased Risk and Faster Progression to Dementia. Curr Alzheimer Res. 2012; Sep 19. [Epub ahead of print].
88. Peters ME, Rosenberg PB, Steinberg M, et al. Neuropsychiatric Symptoms as Risk Factors for Progression From CIND to Dementia: The Cache County Study. Am J Geriatr Psychiatry. 2012; [Epub ahead of print].
89. Shahnawaz Z, Reppermund S, Brodaty H, et al. Prevalence and characteristics of depression in mild cognitive impairment: the Sydney Memory and Ageing Study. Acta Psychiatr Scand. 2012; [Epub ahead of print].
90. Richard E, Schmand B, Eikelenboom P, et al. Symptoms of apathy are associated with progression from mild cognitive impairment to Alzheimer's disease in non-depressed subjects. Dement Geriatr Cogn Disord. 2012;33(2-3):204-209.
91. Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions. Biol Psychiatry. 2012;71(9):814-821.
92. Gallagher D, Coen R, Kilroy D, et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2011;26(2):166-172.
93. Chan WC, Lam LC, Tam CW, et al. Neuropsychiatric symptoms are associated with increased risks of progression to dementia: a 2-year prospective study of 321 Chinese older persons with mild cognitive impairment. Age Ageing. 2011;40(1):30-35.
94. Ryu SH, Ha JH, Park DH, Yu J, Livingston G. Persistence of neuropsychiatric symptoms over six months in mild cognitive impairment in community-dwelling Korean elderly. Int Psychogeriatr. 2011 Mar;23(2):214-220.
95. Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FR. Affective symptoms as predictors of Alzheimer's disease in subjects with mild cognitive impairment: a 10-year follow-up study. Psychol Med. 2010;40(7):1193-1201.
96. Azermai M, Petrovic M, Engelborghs S, et al. The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: a pilot study. Aging Ment Health. 2013;17(1):125-132.
97. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012; 72(1):41-52.
98. Domínguez-Alonso A, Ramírez-Rodríguez G, Benítez-King G. Melatonin increases dendritogenesis in the hilus of hippocampal organotypic cultures. J Pineal Res. 2012;52(4):427-436.
99. Li DQ, Zhou YP, Yang H. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study. Int J Med Sci. 2012;9(3):248-255.
100. Bidzan L, Grabowski J, Dutczak B, Bidzan M. Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer's type dementia. Psychiatr Pol. 2012;46(3):361-372.
101. Chatterjee S, Chen H, Johnson ML, Aparasu RR. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study. Drugs Aging. 2012; 29(10):807-817.
102. Gardette V, Lapeyre-Mestre M, Coley N, et al. Antipsychotic use and mortality risk in community-dwelling Alzheimer's disease patients: evidence for a role of dementia severity. Curr Alzheimer Res. 2012;9(9):1106-1116.